Sign Up to like & get
recommendations!
0
Published in 2021 at "Pediatric pulmonology"
DOI: 10.1002/ppul.25717
Abstract: BACKGROUND The seasonality of Respiratory Syncytial Virus (RSV) epidemics have been disrupted during the Covid-19 pandemic, possibly because of lockdowns and social restrictions reducing viral transmission. Given uncertainties around the severity of upcoming RSV bronchiolitis…
read more here.
Keywords:
bronchiolitis;
risk;
cdh infants;
rsv ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.1304
Abstract: Abstract Background In 2014, the AAP updated guidelines for administration of palivizumab in children at high risk of respiratory syncytial virus (RSV) disease. The updated guidelines defined high risk patient populations and recommended that eligible…
read more here.
Keywords:
asp;
freestanding children;
children hospital;
protocol ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Thorax"
DOI: 10.1136/thoraxjnl-2017-210983.223
Abstract: Introduction Palivizumab is a monoclonal antibody that reduces the likelihood of serious respiratory tract infection by Respiratory Syncytial Virus (RSV) in infants with Chronic Lung Disease (CLD) defined as an ongoing oxygen requirement at 36…
read more here.
Keywords:
aap criteria;
additional babies;
palivizumab;
jcvi criteria ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2021.756787
Abstract: Objective: To define the impact of associated abnormalities on the efficacy of the novel subtropical guidelines for palivizumab prophylaxis on respiratory syncytial virus (RSV)-related hospitalizations in patients with hemodynamically significant congenital heart disease (hsCHD). Method:…
read more here.
Keywords:
palivizumab prophylaxis;
subtropical guidelines;
rsv related;
guidelines palivizumab ... See more keywords